The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer.
Biomarkers, Tumor
/ antagonists & inhibitors
Breast Neoplasms
/ drug therapy
Carcinoma, Ductal, Breast
/ drug therapy
Carcinoma, Intraductal, Noninfiltrating
/ drug therapy
Carcinoma, Lobular
/ drug therapy
Cell Line, Tumor
Cell Survival
/ drug effects
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immunohistochemistry
Middle Aged
Molecular Targeted Therapy
/ methods
Protein Kinase Inhibitors
/ pharmacology
Receptor, ErbB-2
/ metabolism
Receptor, trkA
/ antagonists & inhibitors
Survival Analysis
breast cancer
clinical biomarker
human epidermal growth factor receptor 2 (HER2)
therapeutic target
tyrosine kinase receptor A (NTRK1/TrkA)
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
17 09 2020
17 09 2020
Historique:
received:
19
08
2020
revised:
13
09
2020
accepted:
15
09
2020
entrez:
22
9
2020
pubmed:
23
9
2020
medline:
14
9
2021
Statut:
epublish
Résumé
The tyrosine kinase receptor A (NTRK1/TrkA) is increasingly regarded as a therapeutic target in oncology. In breast cancer, TrkA contributes to metastasis but the clinicopathological significance remains unclear. In this study, TrkA expression was assessed via immunohistochemistry of 158 invasive ductal carcinomas (IDC), 158 invasive lobular carcinomas (ILC) and 50 ductal carcinomas in situ (DCIS). TrkA was expressed in cancer epithelial and myoepithelial cells, with higher levels of TrkA positively associated with IDC (39% of cases) (
Identifiants
pubmed: 32957504
pii: biom10091329
doi: 10.3390/biom10091329
pmc: PMC7564775
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
NTRK1 protein, human
0
Protein Kinase Inhibitors
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Receptor, trkA
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Faculty of Health and Medicine, University of Newcastle Australia
ID : G1101013
Pays : International
Références
FASEB Bioadv. 2020 Jun 30;2(7):398-408
pubmed: 32676580
Nat Med. 2013 Nov;19(11):1469-1472
pubmed: 24162815
Oncogene. 2009 May 7;28(18):1960-70
pubmed: 19330021
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Cytokine Growth Factor Rev. 2012 Dec;23(6):357-65
pubmed: 22749855
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
Clin Cancer Res. 2002 Jun;8(6):1924-31
pubmed: 12060637
Cancer Res. 2001 Jun 1;61(11):4337-40
pubmed: 11389056
Cancer Discov. 2015 Jan;5(1):25-34
pubmed: 25527197
Annu Rev Neurosci. 2006;29:507-38
pubmed: 16776595
ACS Med Chem Lett. 2012 Jan 01;3(2):140-5
pubmed: 24900443
Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32
pubmed: 22124364
Nature. 2014 Sep 18;513(7518):382-7
pubmed: 25043054
J Biol Chem. 2012 Jan 13;287(3):1923-31
pubmed: 22128158
J Biol Chem. 2000 Feb 25;275(8):5388-94
pubmed: 10681513
Breast Cancer Res Treat. 2004 Jan;83(2):119-28
pubmed: 14997042
Am J Pathol. 2018 Jan;188(1):229-241
pubmed: 29037860
Oncotarget. 2015 Apr 30;6(12):10473-86
pubmed: 25871389
Breast Cancer Res. 2017 Jun 5;19(1):65
pubmed: 28583138
Mod Pathol. 2014 Mar;27(3):361-74
pubmed: 23948750
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Mol Cancer Ther. 2004 Dec;3(12):1585-92
pubmed: 15634652
Ann Oncol. 2016 Mar;27(3):480-7
pubmed: 26704052
Mol Cell Biol. 1999 Mar;19(3):1720-30
pubmed: 10022859
Cell. 2016 Apr 21;165(3):535-50
pubmed: 27104977
J Clin Oncol. 2012 Feb 20;30(6):593-9
pubmed: 22124109
Oncotarget. 2016 May 10;7(19):28488-97
pubmed: 27074571
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Nat Rev Genet. 2012 Mar 13;13(4):227-32
pubmed: 22411467
Cell. 2018 Apr 5;173(2):283-285
pubmed: 29625045
PLoS One. 2009 Jul 03;4(7):e6146
pubmed: 19582160
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Oncogene. 2013 Aug 29;32(35):4064-77
pubmed: 23001042
J Biol Chem. 2001 May 25;276(21):17864-70
pubmed: 11359788
Mol Cell Proteomics. 2007 Nov;6(11):1842-54
pubmed: 17617666
Sci Rep. 2018 May 25;8(1):8135
pubmed: 29802376
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Methods Mol Biol. 2012;846:1-12
pubmed: 22367796
Adv Biol Regul. 2015 May;58:16-27
pubmed: 25491371
Clin Exp Metastasis. 2013 Feb;30(2):165-76
pubmed: 22886570
Cancer Res. 2008 Jan 15;68(2):346-51
pubmed: 18199526
Curr Oncol Rep. 2019 Feb 4;21(2):14
pubmed: 30715603
J Neurobiol. 1999 May;39(2):323-36
pubmed: 10235685
Cancer Treat Rev. 2018 Jun;67:10-20
pubmed: 29751334
Oncol Rep. 2019 Nov;42(5):2039-2048
pubmed: 31485624